VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Future Treatment Strategies for NSCLC

Panelists: Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, University of Pittsburgh;Thomas E. Stinchcombe, MD, UNC; Anne S. Tsao, MD, MD Ande
Published: Tuesday, May 05, 2015


Anne S. Tsao, MD, notes that lung cancer is not simply one disease, and more individuals should enroll into clinical trials so that more can be learned regarding how to best treat patients. Tsao adds that it is critical to know whether an individual has adenocarcinoma, squamous cell carcinoma, or neuroendocrine disease.

A number of novel therapies are in development to overcome resistance to established standards of care. While these newer-generation drugs represent a positive first-step, investigators must continually search for more novel approaches in the future, comments Roy S. Herbst, MD.

As new therapies are developed, there is a continued need for better biomarkers. To help discover better predictive markers, Heather A. Wakelee, MD, hopes that future clinical practice incorporate more serum analyses in place of repeating biopsies to assess disease activity. Liquid biopsies are a promising avenue for further development and early detection of disease resistance, adds Thomas E. Stinchcombe, MD. 

Slider Left
Slider Right


Anne S. Tsao, MD, notes that lung cancer is not simply one disease, and more individuals should enroll into clinical trials so that more can be learned regarding how to best treat patients. Tsao adds that it is critical to know whether an individual has adenocarcinoma, squamous cell carcinoma, or neuroendocrine disease.

A number of novel therapies are in development to overcome resistance to established standards of care. While these newer-generation drugs represent a positive first-step, investigators must continually search for more novel approaches in the future, comments Roy S. Herbst, MD.

As new therapies are developed, there is a continued need for better biomarkers. To help discover better predictive markers, Heather A. Wakelee, MD, hopes that future clinical practice incorporate more serum analyses in place of repeating biopsies to assess disease activity. Liquid biopsies are a promising avenue for further development and early detection of disease resistance, adds Thomas E. Stinchcombe, MD. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x